Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.020 -0.630 (-38.18%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2026 Add to My Watchlist

Price and Volume

Volume	11,827,106
Open	1.560
Bid (Size)	1.070 (2,300)
Ask (Size)	1.080 (2,400)
Prev. Close	1.650
Today's Range	0.9697 - 1.610
52wk Range	0.2500 - 3.830
Shares Outstanding	88,268,078
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Keep an eye on the top gainers and losers in Wednesday's session. ↗

Today 15:00 EDT

Via Chartmill

Here are the top movers in Wednesday's session. ↗

Today 12:30 EDT

Via Chartmill

Performance

YTD	-30.6%	-30.6%
1 Month	-17.7%	-17.7%
3 Month	-7.3%	-7.3%
6 Month	-27.1%	-27.1%
1 Year	+293.1%	+293.1%

More News

There are notable gap-ups and gap-downs in today's session. ↗

Today 10:30 EDT

Via Chartmill

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Today 7:30 EDT

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics (NASDAQ:CGTX) Narrows Loss, Eyes Key FDA Meeting on DLB Drug ↗

March 26, 2026

Via Chartmill

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

June 16, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

May 21, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 14, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

May 07, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

What's going on in today's after hours session ↗

April 20, 2026

Via Chartmill

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

April 07, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics CEO Issues Letter to Shareholders

March 31, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

March 26, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

March 23, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

March 17, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

March 02, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

February 05, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

January 27, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

January 06, 2026

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

December 03, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 01, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

November 13, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

November 06, 2025

From Cognition Therapeutics, Inc.

Via GlobeNewswire

Here are the top movers in Monday's session. ↗

September 15, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 15, 2025

Via Benzinga

Frequently Asked Questions

Is Cognition Therapeutics, Inc. - Common Stock publicly traded?

Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?

Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?

The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market

What is the current price of Cognition Therapeutics, Inc. - Common Stock?

The current price of Cognition Therapeutics, Inc. - Common Stock is 1.020

When was Cognition Therapeutics, Inc. - Common Stock last traded?

The last trade of Cognition Therapeutics, Inc. - Common Stock was at 06/24/26 04:00 PM ET

What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?

The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 90.03M

How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?

Cognition Therapeutics, Inc. - Common Stock has 90M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.